Scinai Immunotherapeutics News
114 articles
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract...
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has received a non-dilutive grant of approximately $246,000 from the Israel Innovation Authority. This grant will fund two-thirds of a $373,000 project aimed at enhancing Scinais small-batch fill-and-finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad. The investment will enable Scinai to install an advanced fill-and-finish system for sterile manufacturing, enhancing its capacity and operational flexibility. This development strengthens Scinais role in Israels biopharma manufacturing ecosystem, allowing it to provide high-quality, flexible CDMO services to biotech innovators worldwide. The installation and qualification of the new system are expected in Q1 2026, with commercial operation planned for Q2 2026.
Investment
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and...
Scinai Immunotherapeutics Ltd. reported its financial results for the first half of 2025, showing increased revenues and reduced R&D expenses, leading to a lower net loss compared to the previous year. The companys CDMO business continues to grow, contributing significantly to revenues. Scinai is advancing its anti-IL-17 NanoAb program with plans for clinical trials and has filed patents for new NanoAbs. The company raised $4.2 million through a Standby Equity Purchase Agreement with Yorkville Advisors. Scinai is also pursuing grant financing for further development and has signed an option agreement to acquire PinCell srl, an Italian biotech company.
InvestmentPartnersProduct Stage
growth-positive
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, is set to participate in the BIO International Convention 2025 to showcase its recent advancements. The company raised $1.38 million through a Standby Equity Purchase Agreement with Yorkville Advisors, enhancing its financial flexibility. Scinai is focusing on expanding its CDMO services and advancing its nanobody pipeline. The companys Q1 2025 financial results indicate rapid growth in CDMO revenues, with 2025 revenue expected to reach $2 million. A cost-reduction program is in place to lower expenses and extend financial stability. CEO Amir Reichman aims to explore new collaborations with pharma partners, CDMO clients, and investors.
InvestmentPartnersCustomers
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering...
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, is set to participate in the BIO International Convention 2025 to showcase its strategic advances. The company recently raised $1.38 million through a Standby Equity Purchase Agreement with Yorkville Advisors, enhancing its operational flexibility. Scinai is focusing on expanding its CDMO services and advancing its nanobody pipeline. The company reported rapid growth in CDMO revenues and expects 2025 revenue to reach $2 million. A cost-reduction program has been implemented to lower expenses and extend financial stability. CEO Amir Reichman aims to explore new collaborations with pharma partners, CDMO clients, and investors at the conference.
InvestmentPartnersCustomers
growth-positive
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Scinai Immunotherapeutics Ltd. has received regulatory approval from the Italian government under the Golden Power regulation for its option to acquire Pincell S.r.l., an Italian biotechnology company. This approval marks a significant step in the acquisition process, although the transaction is not yet complete. Scinai entered into a binding option agreement to acquire Pincell in March 2025. Pincells lead candidate, PC111, is a monoclonal antibody in development for severe dermatological conditions and has received Orphan Drug Designation by the European Medicines Agency. Scinais Polish subsidiary has applied for a €12 million grant to support PC111s development, with a decision expected by mid-July to early August 2025.
Acquisition
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological...
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has received regulatory approval from the Italian government under the Golden Power regulation for its option to acquire Pincell S.r.l., an Italian biotechnology company. This approval is a significant step towards finalizing the acquisition, which is contingent on fulfilling additional conditions. Pincells lead candidate, PC111, is a monoclonal antibody in development for severe dermatological conditions and has received Orphan Drug Designation in Europe. Scinais Polish subsidiary has applied for a €12 million grant to support PC111s development. The acquisition is expected to be completed once all conditions, including the grant application outcome, are met.
Acquisition
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and...
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, reported its financial results for the first quarter of 2025. The company saw a revenue increase to $586 thousand, driven by growth in its CDMO business. R&D expenses decreased, contributing to a reduced net loss of $1,557 thousand compared to the previous year. The company focuses on developing biological drug candidates for inflammation and immunology-related diseases and offers CDMO services. Scinais pipeline includes nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs. The company converted an EIB loan into preferred shares, improving its financial position. Scinai faces risks related to revenue expectations, clinical trials, and regulatory approvals.
Product StageInvestment
growth-positive
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, reported its financial results for the first quarter of 2025. The company, which focuses on developing biological drug candidates for inflammation and immunology-related diseases, saw a revenue increase to $586 thousand, driven by growth in its CDMO business. R&D expenses decreased to $1,296 thousand, contributing to a reduced net loss of $1,557 thousand compared to the previous year. The company converted an EIB loan into preferred shares, improving its financial income. Scinais cash and cash equivalents stood at $1,018 thousand as of March 31, 2025. The company continues to develop its pipeline of nanosized VHH antibodies and provide CDMO services for early-stage biotech projects.
Product StageInvestment
growth-positive
Scinai Announces Annual Financial Results for 2024
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, reported its financial results for 2024, highlighting a significant improvement from the previous year. The company generated $658,000 in revenue, primarily from its CDMO services, marking its first revenue generation. R&D expenses slightly increased to $5.6 million, while marketing and administrative expenses decreased to $2.6 million. The company reported a net gain of $4.8 million, a substantial turnaround from a net loss of $6.5 million in 2023, largely due to $14.8 million in financial income from loan conversion to equity. As of December 31, 2024, Scinai had $1.9 million in cash and equivalents.
Product StageCustomers
growth-positive
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, is hosting a webinar to discuss PC111, a novel monoclonal antibody drug candidate for treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. The company announced a binding option agreement to acquire the Italian biotech company Pincell srl. A grant application for Euro 12 million has been submitted by Scinais Polish subsidiary to fund the next development stage of PC111. The webinar will cover unmet needs in treating these diseases, the current standard of care, and the drug development plan for PC111. The event will feature key figures from Scinai and Pincell, and participants can engage in a Q&A session.
AcquisitionProduct Stage
growth-positive
Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating...
Scinai Immunotherapeutics Ltd. has filed for a €12 million grant to fund the next stage of development for PC111, a monoclonal antibody targeting severe skin disorders like Pemphigus and SJS/TEN. The company has entered a binding option agreement to acquire Italian biotech firm Pincell srl, which has developed PC111. The acquisition aims to leverage Pincells expertise in dermatology and Scinais capabilities in biologics development. The grant application is part of the European Funds for a Modern Economy (FENG) program in Poland. Scinai anticipates accelerated approval for PC111 due to its innovative approach and the lack of effective treatments for these conditions.
Product StageAcquisitionInvestment
growth-positive
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has filed an application for a €12 million grant to fund the next stage of development for its monoclonal antibody, PC111. This antibody is being developed to treat Pemphigus, Steven Johnsons Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). PC111 has already received Orphan Drug Designation in Pemphigus by the European Medicines Agency. Scinai plans to file for Orphan Drug and Breakthrough Designation with the FDA. The company has entered into a binding option agreement to acquire the Italian biotech company Pincell srl, which has exclusively licensed PC111 to Scinais Polish subsidiary. The acquisition and grant funding are expected to accelerate the development of PC111.
Product StageAcquisition
growth-positive
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology products, announced its participation in the BIO-Europe Spring 2025 conference in Milan, Italy. The company will showcase its innovative I&I product pipeline and CDMO services. Scinais leadership will meet with potential pharma partners interested in co-developing or in-licensing its NanoAbs, prospective clients for its CDMO services, and institutional and private investors. The company has partnered with Ayana Pharma for liposomal encapsulated drug development services. Scinais CDMO unit, launched in 2024, operates under cGMP conditions and complies with EMA and FDA requirements. The U.S. subsidiary aims to serve early-stage biotech companies with CDMO services.
PartnersInvestment
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological...
growth-positive
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., managed by Yorkville Advisors Global, LP. This agreement allows Scinai to sell up to $10 million of its American Depository Shares to Yorkville over a three-year period, providing flexibility to access additional capital. The funds will support the development of Scinais NanoAbs programs, expand its CDMO business, and cover general corporate purposes. The SEPA offers favorable terms, allowing Scinai to raise capital at a minimal discount without issuing warrants, thus enabling strategic financial planning.
Investment
growth-positive
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology products, announced its participation in upcoming conferences in Miami and San Francisco in January 2025. The companys CEO and Chairman will meet with institutional and private investors, potential pharma partners, and prospective clients for its CDMO services. Scinai is focused on developing nanosized VHH antibodies (NanoAbs) and offers comprehensive biologics CDMO services. The company aims to expand its partnerships and investor base through these events. Scinai has released a video highlighting its 2024 achievements and continues to face risks related to revenue, compliance, and clinical trials.
PartnersInvestment
growth-positive
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has announced the establishment of a U.S.-based subsidiary, Scinai Bioservices Inc., to expand its Contract Development and Manufacturing Services (CDMO). This move is part of Scinais strategy to capitalize on the growing demand for CDMO services for biological early-stage drugs in the U.S. The new subsidiary will operate under cGMP conditions, complying with EMA and FDA requirements. Scinai has partnered with Ayana Pharma to provide liposomal encapsulated drug development services. The expansion aligns with the increasing complexity of biologics and the need for high-quality development and manufacturing capacities. However, the introduction of the BIOSECURE Act could impact U.S. biopharmaceutical drugs partnered with Chinese CDMOs.
PartnersExpand
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has established a U.S.-based subsidiary, Scinai Bioservices Inc., to expand its Contract Development and Manufacturing Services (CDMO) in response to growing demand in the U.S. market. The new subsidiary aims to serve early-stage biotech companies, providing essential CDMO services that are in short supply. Scinai has partnered with Ayana Pharma for liposomal encapsulated drug development and signed its first U.S. contract with Serpin Pharma for clinical manufacturing. The expansion is expected to significantly boost Scinais CDMO business revenues. The company is strategically positioning itself to avoid issues related to the BIOSECURE Act, which restricts U.S. federal funding to foreign adversary biotech companies.
CustomersPartners
growth-positive
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has appointed Prof. Michael Schön to its Scientific Advisory Board. Prof. Schön, a distinguished expert in dermatology and immunology, brings extensive experience in treating chronic inflammatory skin diseases and has a strong background in research and drug development. His appointment is expected to enhance Scinais efforts in advancing its pipeline of innovative inflammation and immunology biological products. The company also congratulated Dr. Jonathan Sadeh, another member of its Scientific Advisory Board, on his new role as Chief Scientific Officer and Chief Medical Officer of Bausch Health. These appointments highlight the high caliber of talent advising Scinais R&D team and board of directors.
Management Changes
growth-negative
There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability
Scinai Immunotherapeutics Ltd. recently reported strong stock performance following its earnings report. However, the companys accrual ratio of 1.22 suggests potential future profitability issues, as it indicates that profits are not backed by free cash flow. Over the past year, Scinai experienced a cash outflow of $6.7 million despite reporting a profit of $4.7 million. Additionally, the company issued new shares, increasing the number of shares by 96%, which diluted shareholder value. This dilution means that while the company reported a profit, the earnings per share were negatively impacted. Investors are advised to be cautious and consider the companys balance sheet strength.
growth-positive
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology biological products, has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board. Dr. Sadeh brings over 20 years of experience in drug development and clinical research, having held senior leadership roles at Bristol-Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough. His expertise will support the advancement of Scinais IL-17 program and VHH antibody pipeline. Dr. Sadehs appointment is seen as a strategic move to enhance Scinais capabilities in developing innovative therapies for unmet medical needs. The collaboration with institutions like Max Planck and UMG is expected to further bolster Scinais position in the field.
Management Changes
growth-positive
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board. Dr. Sadeh brings over 20 years of experience in drug development and clinical research, having held senior positions at Bristol-Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough. His expertise will aid in advancing Scinais IL-17 program and other assets in their VHH antibody pipeline. The appointment is seen as a positive step for Scinai, enhancing its capabilities in developing innovative therapies for unmet medical needs. Scinai operates two business units: one for developing inflammation and immunology biological products and another providing CDMO services. The company aims to establish itself as a leader in scientifically driven drug development.
Management Changes
growth-positive
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, announced the conversion of a significant loan from the European Investment Bank (EIB) into equity. This conversion involved approximately EUR 26.6 million ($28.1 million) being converted into 1,000 preferred shares, representing 19.5% of the companys fully diluted capital stock. The restructuring reduced the companys outstanding debt to the EIB to EUR 250,000 ($264,000), with a maturity date of December 31, 2031. This financial maneuver helped Scinai regain compliance with Nasdaqs listing requirements, specifically maintaining a stockholders equity of at least $2.5 million. The transaction is seen as a positive step for the company, enhancing its financial stability and market position.
Investment
growth-positive
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology products, announced its participation in the BIO-Europe 2024 conference in Stockholm, Sweden, from November 4-6. The company aims to showcase its innovative product pipeline and CDMO services. Scinais CEO and CTO will engage with prospective clients and potential pharma partners interested in co-developing or in-licensing their NanoAbs and dermatology drug development programs. The conference provides an opportunity for Scinai to expand its partnerships and attract institutional and private investors. The event is seen as a growth-positive step for Scinai, enhancing its visibility and potential collaborations in the biopharmaceutical sector.
Partners
growth-positive
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai Immunotherapeutics Ltd. announced it will host a scientific webinar on September 18, 2024, to discuss unmet needs in treating mild to moderate plaque psoriasis. The webinar will explore the potential of Scinais novel anti-IL-17A/F VHH antibody for intralesional injections. The event will feature key executives and experts, including CEO Amir Reichman and Chief Scientific Officer Dr. Tamar Ben Yedidia. Topics will cover the plaque psoriasis landscape, current treatment options, and the advantages of VHH antibodies. The webinar aims to provide insights into Scinais pipeline and drug development journey.
growth-positive
Scinai Regains Full Compliance with Nasdaq Listing Requirements
Scinai Immunotherapeutics Ltd. announced that it has regained compliance with Nasdaqs listing requirements by converting approximately $29 million of debt into preferred equity, leaving a minimal debt balance. This compliance was confirmed by Nasdaq on August 27, 2024. The company is now focused on its R&D programs and its new CDMO business unit. The European Investment Bank played a key role in this financial restructuring. Scinai will be under a one-year mandatory monitoring period by Nasdaq to ensure continued compliance.
Investment
Growth-Positive
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
Scinai Immunotherapeutics Ltd. has closed a Loan Restructuring Agreement with the European Investment Bank (EIB). As part of the agreement, an amount of approximately EUR 26.6 million owed by Scinai to the EIB was converted into 1,000 preferred shares of the company. Following this conversion, Scinai owes the EIB EUR 250,000, which is not due until December 31, 2031. As a result of the restructuring, Scinais equity is above $2.5 million, in compliance with Nasdaq Listing Rules. The preferred shares are convertible into ADSs, do not accrue dividends, and are redeemable at the companys discretion.
Investment
growth-positive
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
Scinai Immunotherapeutics Ltd. has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of Mr. Daniel Stone, the largest shareholder of the Company. The Company may issue and sell ADSs to the Investor, from time to time through December 31, 2024, for an aggregate purchase price of up to $2 million. The Agreement also includes standard representations, warranties and covenants of the parties and conditions to closing of each advance.
Investment
growth-positive
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
Scinai Immunotherapeutics Ltd. has published its Q2 2024 financial results and provided a business update. The company has restructured a $29 million bank loan to equity and is on track to regain NASDAQ compliance by August 23, 2024. The companys CDMO business unit has received work orders valued at approximately $600K since January 2024 and is in advanced contract discussions with several other potential clients. The company is also advancing its NanoAb preclinical development and has announced promising results for its treatment of plaque psoriasis.
InvestmentPartners
growth-positive
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Scinai Immunotherapeutics Ltd. has signed a Loan Restructuring Agreement with the European Investment Bank (EIB). The agreement will convert approximately EUR 26.6 million of the companys debt into 1,000 preferred shares, reducing the outstanding loan amount to EUR 250,000. The new loan will mature on December 31, 2031, and will not accrue interest. The preferred shares are convertible into a fixed number of ADSs equal to 19.5% of the companys fully diluted capital. The restructuring will eliminate almost $28 million of debt and is expected to provide a more stable financial base for Scinai.
Investment
growth-positive
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
Scinai Immunotherapeutics has received positive regulatory feedback from the Paul Erlich Institute (PEI) for its drug development program. The PEI accepted Scinais position to conduct toxicology studies in pigs rather than in Non-Human Primates, and to compare the SCN-1 to placebo directly in patients with mild to moderate plaque psoriasis, skipping the need for testing in healthy volunteers. This will result in a phase 1/2a clinical trial, assessing both safety and efficacy in the same trial. The trial is expected to commence in the second half of 2025 with results in 2026.
CustomersManagement Changes
growth-positive
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
Scinai Immunotherapeutics Ltd. has announced successful in-vivo preclinical study results of its innovative anti IL-17A/F VHH antibody fragment (NanoAb) as a local, first of its kind, intralesional biological treatment for patients suffering from mild to moderate plaque psoriasis. The companys product candidate is designed to address the major shortcomings of currently available treatments. The study was conducted by the team of Prof. Amos Gilhar at the Technion, Israel Institute of Technology, Haifa. Scinai next intends to conduct a longer duration follow on in-vivo animal study in late 2024, complemented by a pre-clinical toxicology study before commencing a first-in-human clinical trial in late 2025.
InvestmentExpand
growth-positive
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
Scinai Immunotherapeutics Ltd. has received an updated non-binding Letter of Intent from the European Investment Bank (EIB) to convert the majority of the EIBs loan into equity. This conversion would be in the form of preferred shares, which are convertible into American Depositary Shares representing 19.5% of the fully diluted capital of the company. The loan to be converted is approximately $28 million. The company believes that this conversion would eliminate the shareholders deficit and create a shareholders equity surplus. This move is part of the companys plan to regain compliance with the Nasdaqs Equity Requirement.
Investment
Growth-Negative
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Scinai Immunotherapeutics Ltd., a biotechnology company, has been granted a request to continue its listing on The Nasdaq Stock Market, subject to meeting certain conditions. The company had previously received a letter from Nasdaq stating that it was not in compliance with the minimum stockholders equity requirement for continued listing. Scinai presented a plan to address the Equity Requirement matter by converting a significant portion of the loan owed by the company to the European Investment Bank into equity. The company has been given until August 14, 2024, to demonstrate compliance.
Public Trading
growth-positive
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has published its financial results for Q1 2024 and provided a business update. The company raised $1.69 million in gross proceeds from the exercise of certain of its outstanding warrants and the issuance of new warrants. It also regained compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The company is working on a debt-to-equity loan restructuring deal with the European Investment Bank (EIB). Scinais CDMO business unit received work orders valued at approximately $500K and is in advanced contract discussions with several other potential clients.
InvestmentExpand
growth-positive
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
Scinai Immunotherapeutics Ltd. has received a non-binding Letter of Intent from the European Investment Bank (EIB) outlining terms for converting the EIBs loan into equity. The loan conversion, worth approximately $27.6 million, would eliminate the shareholders deficit of $4.5 million and create an estimated shareholders equity surplus of approximately $14.5 million. This move is expected to improve Scinais standing in the financial community and help it regain compliance with Nasdaqs minimum shareholders equity requirement. The company plans to present its plan to regain and remain compliant with the Rule during its upcoming meeting with the Nasdaq Hearings Panel on June 18, 2024.
Investment
growth-positive
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
Scinai Immunotherapeutics Ltd. has regained compliance with Nasdaqs minimum bid price requirement. The biotech company had previously been noncompliant, but regained compliance after a ratio change of its American Depositary Shares (ADSs) to its non-traded ordinary shares. The company is also in discussions with the European Investment Bank (EIB) to convert a significant portion of the loan owed by the company to EIB into equity. The potential conversion is considered a key component of the companys plan to regain compliance with Nasdaqs minimum shareholders equity requirement.
InvestmentPublic Trading
growth-negative
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance
Scinai Immunotherapeutics Ltd. has received a notice of noncompliance from Nasdaq due to not meeting the minimum shareholders equity required for continued listing. The company is planning a hearing with the Nasdaq Hearings Panel to present a plan to regain compliance. One of the components of the plan could include conversion of a part of the companys loan from the European Investment Bank into equity. The company also received a second notice of noncompliance for not meeting the minimum stockholders equity requirement for continued listing on the Nasdaq Capital Market. The companys ADSs will continue to trade on the Nasdaq Capital Market under the symbol SCNI.
InvestmentPublic Trading
growth-positive
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
Scinai Immunotherapeutics Ltd. has published its full-year financial results for 2023 and provided a business update. The company raised $1.69 million in gross proceeds from the exercise of certain of its outstanding warrants and the issuance of new warrants. The Israel Innovation Authority approved a non-dilutive grant reimbursing Scinai for 66% of the costs of a project valued at NIS 3.5 million. The company is also in advanced contract discussions with several other potential clients for its CDMO business unit. Scinai is aggressively advancing the NanoAb preclinical development and is pursuing a strategic partnership for both its COVID-19 self-administered inhaled NanoAb and for its anti-IL-17 nanoAb.
InvestmentExpand
growth-negative
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
Scinai Immunotherapeutics Ltd. has received a staff determination letter from the Nasdaq Stock Market LLC, notifying the company of its non-compliance with the minimum $1.00 bid price requirement. As a result, the companys American Depositary Shares (ADSs) are scheduled for delisting from The Nasdaq Capital Market. The company has appealed the delisting determination and requested a hearing. The Board of Directors has approved a ratio change of the ADSs to its non-traded ordinary shares, equivalent to a reverse split of 1 for 10, in an attempt to correct the non-compliance issue.
Public TradingManagement Changes
growth-positive
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
Scinai Immunotherapeutics Ltd. announced that its Chief Science Officer, Dr. Tamar Ben-Yedidia, and Prof. Michael Schön, Director of the Department of Dermatology, Venereology & Allergology at the University Medical Center Göttingen, will be presenting at the 5th Dermatology Drug Development Summit Europe in Berlin. They will discuss the use of Scinais NanoAbs as a local treatment for plaque psoriasis. Scinais CEO, Mr. Amir Reichman, will also participate in a panel discussion. The companys Anti-IL-17A/F NanoAbs are designed to address large unmet therapeutic needs of mild to moderate plaque psoriasis patients.
Partners
growth-positive
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
Scinai Immunotherapeutics Ltd. has signed a five-year Master Service Agreement (MSA) with Ayana Pharma Ltd. Under the agreement, Scinai will provide drug development and cGMP manufacturing services to Ayana. The partnership is expected to generate at least $1.8 million in revenues for Scinai over the next five years. Scinais COO, Elad Mark, expressed his pleasure in welcoming Ayana as a client and highlighted the capabilities of Scinai Bioservices in supporting Ayanas liposomal product portfolio drug development needs.
PartnersCustomers
growth-positive
Scinai leadership to attend BIO-Europe Spring 2024
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, announced its participation in the BIO-Europe Spring 2024 conference in Barcelona. The company will be showcasing its cGMP biologics CDMO services and innovative NanoAb pipeline. It is also looking to engage with prospective clients, potential pharma partners in the field of dermatology, and institutional and private investors. The companys CEO, Amir Reichman, provided an overview of Scinais assets and plans in an introductory video.
PartnersCustomersInvestment
Growth-Positive
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, announced its participation in the MIXiii International Life Science and Health-tech Conference in Jerusalem. The companys leadership team will be available for discussions with potential clients, pharmaceutical industry partners, and investors. Scinai will also be participating in the Bio Europe Spring conference in Barcelona, Spain. The company is focused on developing inflammation and immunology biological products and providing CDMO services through its Scinai Bioservices business unit.
CustomersPartners
growth-positive
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
Scinai Immunotherapeutics Ltd. has announced the appointment of Liat Halpert as Head of Business Development and Sales. Halpert, who has extensive pharmaceutical sales and marketing experience, joins Scinai after 14 years at Novartis. Her initial focus will be to expand the business by targeting European and US-based biotech companies to support further growth of the CDMO business. Scinais R&D unit is focused on developing an innovative pipeline of nanosized VHH antibodies (NanoAbs) licensed from the Max Planck Society and the University Medical Center Göttingen in Germany. The company plans to enter human clinical trials in 2025.
Management ChangesExpand
growth-positive
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
Scinai Immunotherapeutics Ltd. congratulates its co-lead scientific research collaborator, Professor Dr. Dirk Görlich, on being awarded the 2024 Louis-Jeantet Prize. The prize, worth CHF 500,000 (US$ 576,000), is given annually to European-based researchers for groundbreaking work in biomedicine. Görlich, a director of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT), works closely with Scinai on the discovery of nanosized VHH antibodies (NanoAbs), which form the basis of Scinais pipeline targeting inflammation and immunology (I&I) biological therapeutic diseases.
Partners
growth-positive
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
Scinai Immunotherapeutics Ltd. has published a letter from its CEO, Amir Reichman, outlining the companys accomplishments in 2023 and its plans for 2024. The company has seen success in preclinical trials of its anti-IL-17 NanoAb psoriasis therapy and plans to initiate human clinical trials for the therapy in early 2025. Scinai also plans to grow its CDMO business and strengthen its pipeline through collaborations. The European Investment Bank has extended its financial facility with Scinai until December 31, 2031, providing the company with time to develop its pipeline and build its CDMO business.
InvestmentExpand
Growth-Positive
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
Scinai Immunotherapeutics Ltd. has closed its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 2,606,552 American Depositary Shares (ADSs) at a reduced exercise price of $0.65 per ADS. The company has also issued new unregistered warrants to purchase up to 5,213,104 ADSs. The gross proceeds from the exercise of the warrants were approximately $1.69 million. The company plans to use the net proceeds for general working capital, research and development, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Investment
Growth-Positive
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
Scinai Immunotherapeutics Ltd. has announced the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,606,552 American Depositary Shares (ADSs) at a reduced exercise price. The company will issue new unregistered warrants to purchase up to 5,213,104 ADSs. The gross proceeds from the exercise of the warrants are expected to be approximately $1.69 million. The company intends to use the net proceeds for general working capital, research and development, and general corporate purposes. The closing of the offering is expected to occur on or about January 3, 2024.
Investment
growth-positive
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, announced that it will host an analyst and investors webinar event on January 9, 2024. CEO Amir Reichman will review the companys 2023 accomplishments and discuss 2024 plans, including the intention to bring Scinais anti-IL-17 VHH antibody (NanoAb) innovative psoriasis treatment into clinical trials by the end of the year. The company is also focused on the development of inflammation and immunology (I&I) biological products and provision of boutique CDMO services.
Management Changes
growth-positive
Scinai Announces Promising Results in a Psoriatic Human Skin Model
Scinai Immunotherapeutics Ltd. has announced successful preclinical trial results for its anti–IL–17 VHH antibody (NanoAb) as a local treatment for mild to moderate plaque psoriasis. The study was conducted by Genoskin, a French biotechnology company. The results demonstrated the potential for Scinais NanoAbs to improve psoriatic skin lesions. Scinais Chief Scientist, Dr. Tamar Ben-Yedidia, said the results marked a significant step forward in the development of a novel treatment for the undertreated segment of mild and moderate plaque psoriatic patients. Scinai plans to conduct an in-vivo proof of concept animal study in early 2024 in collaboration with the Technion Israel Institute of Technology.
CustomersPartnersExpand
growth-positive
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
Scinai Immunotherapeutics has announced the publication of an article discussing a new generation of anti-SARS-CoV-2 NanoAbs, developed in collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen. The NanoAbs are alpaca-derived recombinant variable domain of heavy-chain-only antibodies. The article covers aspects including their structure, mechanism of action, neutralization of a wide range of SARS-CoV-2 variants, and formulation into aerosols. The company is currently marketing this COVID-19 project for partnering with pharma companies or governmental health agencies.
PartnersCustomers
Growth-Positive
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
Scinai Immunotherapeutics Ltd. has announced an amendment to its finance contract with the European Investment Bank (EIB), extending the maturity date by four years to December 31, 2031. This amendment reflects Scinais strategic shift towards the development of nanosized antibody therapeutics for inflammation and immunology diseases. The extension is expected to have a significant positive impact on Scinais financial health. The amendment also played a part in Nasdaqs determination that Scinai regained compliance with its Listing Rule requiring minimum stockholders equity of $2.5 million.
InvestmentPartners
growth-positive
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
Scinai Immunotherapeutics Ltd. has announced an amendment to its finance contract with the European Investment Bank (EIB), extending the maturity date by four years to December 31, 2031. This amendment reflects Scinais strategic shift towards the development of nanosized antibody therapeutics for inflammation and immunology diseases. The extension is expected to have a significant positive impact on Scinais financial health, aiding in the development of the company. The amendment also played a part in Nasdaqs determination that the company regained compliance with its Listing Rule requiring minimum stockholders equity of $2.5 million.
InvestmentPartners
growth-positive
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule
Scinai Immunotherapeutics Ltd. has regained compliance with Nasdaq listing rules regarding minimum stockholders equity. The biopharmaceutical company, which focuses on developing, manufacturing, and commercializing innovative inflammation and immunology biological products, has been notified by Nasdaq that it complies with Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum $2.5 million in stockholders equity. This determination is based on the content of the Companys Form 6-K dated November 13, 2023. However, Nasdaq also indicated that if the Company does not evidence such compliance in its next periodic report, it may be subject to delisting.
InvestmentPublic Trading
Growth-Positive
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
Scinai Immunotherapeutics Ltd. has received a non-dilutive grant from the Israel Innovation Authority (IIA) that covers 66% of the costs of a project worth approximately US$900,000. The project aims to expand Scinai’s new Contract Development and Manufacturing Organization (CDMO) business unit. The grant is not subject to repayment or tied to royalty payments. The IIA grant will be used for purchasing additional equipment and other investments to position Scinai as a provider of CDMO services at high international standards.
InvestmentExpand
Growth-Negative
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has been notified by Nasdaq about its non-compliance with the minimum bid price requirement. The company has been given 180 days to regain compliance. This comes in addition to a previous deficiency letter from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement. Scinais primary creditor, the European Investment Bank (EIB), is considering adjusting the terms of its financial facility contract with the company, which could positively impact Scinai’s shareholders’ equity and help restore compliance with Nasdaq Listing Rules.
Investment
Growth-Positive
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has announced that its primary creditor, the European Investment Bank (EIB), is considering adjusting the terms of its financial facility contract with the company. This adjustment could extend the facilitys maturity and improve Scinais shareholders equity. The potential extension could help the company comply with Nasdaqs minimum shareholders equity rules. Scinais CEO, Amir Reichman, expressed gratitude for EIBs support and stated that the adjustment could provide financial relief and help the company grow. However, there is no guarantee that the EIB will approve the adjustment.
Investment
growth-negative
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
Scinai Immunotherapeutics Ltd has released its financial results for Q3 2023, showing a net income of $3.1 million, compared to a loss of $4.7 million in the same period in 2022. The company also announced a strategic pivot, raising $1.33 million in gross proceeds via a direct offering with H.C. Wainwright & Co. The European Investment Bank (EIB) is considering adjusting the terms of its financial facility contract with Scinai. The company also secured its first contract to provide CDMO services in October 2023 and is in advanced discussions with several other potential clients.
InvestmentManagement Changes
growth-positive
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
Scinai Immunotherapeutics Ltd. announced that it will be showcasing its CDMO services and its in-house nanosized VHH antibody-based therapeutics pipeline at BIO-Europe, a premier pharmaceutical industry partnering event. The company is seeking partnerships for its pipeline of novel therapies. Scinais CDMO offers biologic drugs process development and scale-up for protein-based drugs, analytical method development for QC testing and cGMP manufacturing. In parallel, Scinai’s in-house R&D program is focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.
Partners
growth-positive
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
Scinai Immunotherapeutics Ltd. announced its participation in the CPHI Barcelona trade show from October 24 to 26, 2023, where it will showcase its Contract Development and Manufacturing Organization (CDMO) services. The companys CDMO offers process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing to biopharmaceutical and biotech clients. Scinais executive leadership team will be available to meet with potential partners and clients. The company will also attend BIO-Europe in Munich and MIXiii Health-Tech.IL in Jerusalem.
PartnersExpand
Growth-Positive
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
Scinai Immunotherapeutics Ltd. has announced the closing of its registered direct offering of 1,146,552 of the Company’s American Depositary Shares (ADSs), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.16 per ADS. Concurrently, the Company has issued unregistered warrants to purchase up to 1,146,552 ADSs representing ordinary shares. The gross proceeds from the offering are approximately $1.33 million. The Company intends to use the net proceeds for general working capital, research and development, and general corporate purposes.
Investment
growth-positive
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
Scinai Immunotherapeutics Ltd. has announced a definitive agreement for the purchase and sale of 1,146,552 of the Company’s American Depositary Shares (ADSs) at a purchase price of $1.16 per ADS in a registered direct offering. Concurrently, the Company will issue unregistered warrants to purchase up to 1,146,552 ADSs. The gross proceeds from the offering are expected to be approximately $1.33 million. The Company plans to use the net proceeds for general working capital, research and development, and general corporate purposes. The closing of the offering is expected to occur on or about September 19, 2023.
Investment
growth-positive
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
Scinai Immunotherapeutics Ltd. has announced positive results from a preclinical study of its anti-interleukin 17 (IL-17) NanoAbs for the treatment of plaque psoriasis. The NanoAbs, derived from alpacas, were tested in a 3D biologic skin model and showed potential to relieve symptoms of plaque psoriasis. The NanoAbs are designed to be administered locally to the dermis and are engineered to degrade in a way that should prevent systemic side effects. The company is now evaluating the NanoAbs in a full human skin model, with in-vivo animal studies anticipated in early 2024.
InvestmentPartners
Growth-Positive
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, announced that its CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston. The company is inviting investors and potential business partners to meet with its senior leadership team. Scinai is focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.
InvestmentPartners
growth-positive
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
BiondVax Pharmaceuticals Ltd. has announced a change of its corporate name to Scinai Immunotherapeutics Ltd. The company has revamped its senior management team and pharmaceuticals development programs over the past two years and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, approved by the Israeli authorities, is the company’s latest step to better reflect its fresh start and new direction. Scinai has established a collaboration with the Max Planck Society and the University Medical Center Göttingen to develop a pipeline of novel NanoAbs. The companys CEO expressed optimism about Scinai’s growth potential and ability to deliver value to stakeholders.
Management ChangesExpand
growth-negative
BiondVax Reports Second Quarter Financial Results and Provides Business Update
BiondVax Pharmaceuticals Ltd. has released its financial results for Q2 2023, revealing a net loss of $3.76 million compared to $2.98 million for the same period in 2022. The companys operating expenses for Q2 2023 were $2.56 million, down from $3.26 million in Q2 2022. As of June 30, 2023, BiondVax had cash and cash equivalents of $7.6 million, compared to $14.2 million as of December 31, 2022. The company is planning to finance its operations from its existing working capital resources and additional sources of capital and financing. It has also approved a cost-saving plan, which includes reducing headcount and postponing or cancelling capital expenditures.
InvestmentManagement Changes
Growth-Positive
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
BiondVax Pharmaceuticals Ltd. has been granted an extension until October 30, 2023, by Nasdaq to demonstrate compliance with Nasdaqs Listing Rule 5550(b). The company had received a deficiency letter from Nasdaq on May 1, 2023, indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. BiondVax is pursuing a strategic partnership for its COVID-19 self-administered inhaled therapeutic/prophylactic product and is advancing its IL-17 NanoAb inhibitor for the treatment of autoimmune diseases. The company is also starting a new contract manufacturing and development services business unit (CDMO) to generate income.
PartnersExpand
growth-positive
BiondVax bets on alpacas to treat psoriasis
BiondVax Pharmaceuticals, an Israeli antibody therapies company, is planning a revival after a failed clinical trial for its universal flu vaccine led to a significant drop in its market cap. CEO Amir Reichman, with experience in setting up vaccine plants and managing supply chains, plans to convert BiondVaxs plant into a manufacturing plant for other companies. Reichman also plans to produce vaccines and other biological products for Israeli startups conducting clinical trials. The companys long-term plan is based on patented products from the Max Planck Institute, including eight antibodies for autoimmune diseases. BiondVax is currently developing a product for psoriasis.
InvestmentManagement ChangesExpand
growth-positive
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd. has raised $8 million in a financing round and has started negotiations to in-license the next antibody from the Max Planck Institute for the treatment of psoriasis. The companys pipeline is based on an innovative platform technology of alpaca-derived nanosized antibodies, known as Nanobodies or NanoAbs, addressing infectious and autoimmune diseases with large unmet medical needs such as COVID-19, psoriasis, psoriatic arthritis, asthma and macular degeneration. The company expects to complete a proof-of-concept trial later this year, followed later by human clinical trials.
InvestmentExpand
growth-positive
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
BiondVax Pharmaceuticals Ltd. has announced a collaboration with Max Planck Society and the University Medical Center Gottingen (UMG) to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for all potential indications, starting with psoriasis and psoriatic arthritis. The global biologics treatment market for psoriasis is over $9 billion per year and growing at a 7% CAGR. BiondVax will lead the development and commercialization of the NanoAbs, with ex vivo proof-of-concept expected this year and in vivo early next year.
PartnersExpand
growth-positive
BVXV: Developing anti-IL-17 NanoAb
BiondVax Pharmaceuticals Ltd. has signed a five-year research collaboration agreement with the Max Planck Society and the University Medical Center Göttingen to develop innovative immunotherapeutic products for infectious and autoimmune diseases. The company is focusing on the development of VHH antibodies, or NanoAbs, for up to nine molecular targets. BiondVax plans to obtain an exclusive license for NanoAbs targeting immune system cytokines such as IL-17 as a potential treatment for psoriasis. The company also announced positive results from a preclinical study of its inhaled anti-COVID-19 NanoAb therapy.
PartnersExpand
growth-negative
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
BiondVax Pharmaceuticals Ltd. has published its Q1 2023 financial results, showing an increase in R&D expenses and a net loss of $3.5 million. The company is offering its cGMP manufacturing capabilities to interested parties, which may generate revenues and allow the company to focus on its NanoAb pipeline development. BiondVax also shared positive preclinical data indicating that its innovative inhaled anti-SARS-CoV-2 NanoAb virtually prevented illness when administered prophylactically. The company is seeking scientific and business development collaborations and has attended several biotech conferences.
Investment
growth-positive
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
BiondVax Pharmaceuticals Ltd. has published its full-year financial results for 2022 and provided a business update. The company signed agreements with the Max Planck Society and the University Medical Center Göttingen to develop bio-better nanosized VHH antibodies (NanoAbs). BiondVax is also planning to commence a Phase 1/2a clinical trial for the treatment and prophylactic prevention of COVID-19. The company reported a net loss of $5.8 million for 2022, compared to a loss of $8.2 million for 2021. As of December 31, 2022, BiondVax had cash and cash equivalents of $14 million.
PartnersInvestment
growth-positive
BiondVax to Present at BIO-Europe Spring
BiondVax Pharmaceuticals Ltd. announces that its CEO, Amir Reichman, will be presenting at the 17th annual BIO-Europe Spring in Basel, Switzerland. The presentation will focus on the companys recent successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans, including nanosized VHH-antibodies (NanoAbs) for the treatment of autoimmune diseases. The companys R&D strategy includes generating a pipeline of bio-better NanoAbs aimed at molecular targets validated by currently approved monoclonal antibodies addressing diseases with underserved medical needs.
PartnersExpand
growth-positive
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
BiondVax Pharmaceuticals Ltd. CEO, Amir Reichman, discusses the companys strategic partnerships and development pipeline on the Test. Optimize. Scale. podcast. Reichman shares his professional journey and the growth of BiondVax, which is now developing a de-risked pipeline of diversified and commercially viable products. The company is focusing on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company has executed eight clinical trials and has built a state-of-the-art manufacturing facility for biopharmaceutical products.
PartnersInvestmentManagement Changes
growth-positive
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals Ltd., recently appeared on the podcast Test. Optimize. Scale. where he discussed his professional journey and the growth of BiondVax. Reichman shared his experiences from his early career, including his work on a patent for drug delivery across the skin for the treatment of Parkinson’s disease, which won a $1 million grant from the Michael J. Fox Foundation for Parkinson’s Research. He also discussed the sale of a company he started, NeuroDerm, to Mitsubishi Tanabe Pharma for $1.1 billion in cash. Reichman joined BiondVax in 2021 and is now developing a de-risked pipeline of diversified and commercially viable products and platforms.
InvestmentManagement Changes
growth-positive
BiondVax Presenting at BIO CEO & Investor Conference
BiondVax Pharmaceuticals Ltd., a biotechnology company specializing in immunotherapeutic products, announced that its CEO, Amir Reichman, will present at the BIO CEO & Investor Conference. The presentation will focus on recent successful preclinical in vivo results of BiondVaxs innovative inhaled COVID-19 treatment and additional pipeline plans. These plans include nanosized VHH-antibodies (NanoAbs) for the treatment of autoimmune diseases, such as psoriasis, asthma, psoriatic arthritis, and macular degeneration. Reichman and Mark Germain, BiondVaxs chairman of the board, will be available to meet potential partners, collaborators, and investors.
Management ChangesExpand
growth-positive
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
BiondVax Pharmaceuticals has announced additional results from a preclinical study of its NanoAb COVID-19 drug. The study found that hamsters given a mid-sized dose of the drug before infection experienced no significant weight loss, compared to a 12% average weight loss in the untreated control group. The company is continuing the trial with lower therapeutic doses and plans to conduct a preclinical toxicity study in 2023. BiondVax also plans to scale up its manufacturing processes for the first-in-human Phase 1/2a trial, planned for Q4 2023.
InvestmentExpand
growth-positive
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
BiondVax Pharmaceuticals Ltd. has announced positive results from a preclinical study of its inhaled NanoAb COVID-19 drug. The study found that hamsters administered the drug three hours prior to infection experienced no significant weight loss over the six-day trial, compared to a 12% average weight loss in the untreated control group. The company plans to conduct a first-in-human Phase 1/2a clinical trial in 2023. The NanoAb is part of a new pipeline of drugs addressing diseases with large underserved medical needs and attractive commercial opportunities.
InvestmentExpand
growth-positive
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
BiondVax Pharmaceuticals Ltd. has announced successful results from a preclinical study of its inhaled nanosized antibody (NanoAb) COVID-19 therapy. The study found that hamsters infected with SARS-COV-2 and treated with BiondVax’s NanoAbs had over 30 times lower lung viral titer compared to those treated with a placebo. The company plans to continue the study by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic treatment. BiondVax is also preparing for the first-in-human Phase 1/2a clinical trial of the inhaled NanoAb COVID-19 therapy, planned for late 2023. The company is also developing a pipeline of NanoAb therapies for diseases such as psoriasis and asthma.
InvestmentExpand
Growth-Positive
BiondVax to Present at Biotech Showcase 2023
BiondVax Pharmaceuticals Ltd., a biotechnology company, announced that its CEO, Amir Reichman, will present at the Biotech Showcase conference in January 2023. The presentation will focus on the companys recent successful preclinical in vivo trial results of its inhaled COVID-19 therapy and additional pipeline plans including a nanosized VHH-antibody (NanoAb) targeting IL-17 for the treatment of autoimmune diseases. Reichman and BiondVax’s Chairman of the Board, Mark Germain, will be available to meet potential partners, collaborators, and investors during the conference.
PartnersInvestment
growth-positive
BiondVax CEO Issues Letter to Shareholders
BiondVax Pharmaceuticals Ltd., a biotechnology company, has published a letter from its CEO, Amir Reichman, outlining the companys achievements in 2022 and its plans for 2023. The company has successfully completed preclinical trials of its inhaled COVID-19 NanoAb therapy and secured financing to support its objectives for the coming year. BiondVax has also signed exclusive agreements with the Max Planck Institute for Multidisciplinary Sciences (MPI) and the University Medical Center Göttingen, Germany (UMG) to develop new VHH nanosized antibodies (NanoAbs). The company plans to bring its inhaled COVID-19 NanoAb therapy into a first-in-human Phase 1/2a clinical trial by the end of 2023.
PartnersInvestmentExpand
growth-positive
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company based in Israel, has raised $8 million in an underwritten public offering with Aegis Capital Corp. acting as the sole bookrunner. The company focuses on the development, manufacturing, and commercialization of products for the prevention and treatment of infectious diseases and other illnesses. BiondVax has a licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb) and other disease indications.
InvestmentPublic Trading
growth-positive
BiondVax Announces Closing of $8 Million Underwritten Public Offering
BiondVax Pharmaceuticals Ltd. has announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units. The company plans to use the net proceeds from the offering for the advancement of its NanoAbs development program, as well as general corporate purposes. Aegis Capital Corp. acted as the sole book-running manager for the offering. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Aegis Capital Corp.
InvestmentPublic Trading
growth-positive
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
BiondVax Pharmaceuticals Ltd. has announced the pricing of its underwritten public offering, with gross proceeds expected to be approximately $8,000,000. The offering consists of 1,600,000 units and pre-funded units. The company plans to use the net proceeds from the offering for the advancement of its NanoAbs development program, as well as for general corporate purposes. The offering is expected to close on December 20, 2022.
InvestmentPublic Trading
Growth-Positive
BiondVax Regains Nasdaq Compliance
BiondVax Pharmaceuticals Ltd., a biotechnology company, has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity and minimum bid price. The company had previously received non-compliance notifications in September and November 2022. However, based on the companys third-quarter financial results and the fact that the minimum bid price has now closed over $1.00 per share for the past ten trading days, Nasdaq has confirmed that the company now complies with its listing rules.
Public Trading
growth-positive
BVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb…
BiondVax Pharmaceuticals Ltd. announced positive preclinical results for its inhaled anti-COVID-19 NanoAb therapy on November 29, 2022. The study showed that the therapy contributed to a milder and shorter illness. The company plans to continue the study next year, testing additional dose levels and its use as a prophylactic treatment. BiondVax also announced financial results for the third quarter of 2022, reporting no revenues and an increase in R&D expenses due to the development activities related to the COVID-19 NanoAb program. The company has sufficient capital to fund operations for the next 12 months.
InvestmentExpand
growth-positive
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd. has announced a partnership with IBN, a financial news and publishing company, to improve its corporate communications. The biopharmaceutical company is working with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to develop nanosized antibody therapies for diseases such as COVID-19, asthma, and psoriasis. IBN will use its distribution network to increase awareness of BiondVax Pharmaceuticals. The company is planning a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023.
PartnersExpand
growth-positive
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
BiondVax Pharmaceuticals Ltd. has announced the appointment of Professor Dr. med. Matthias Dobbelstein to the companys Scientific Advisory Board (SAB). Professor Dobbelstein has been collaborating with BiondVax under a five-year strategic research agreement for the discovery, characterization, and cloning of additional NanoAbs for the treatment of autoimmune diseases. His research forms the scientific basis of BiondVax’s exclusive license for development and commercialization of an innovative, self-administered, inhaled NanoAb for the treatment of COVID-19. The company is focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases.
Management ChangesPartners
Growth-Positive
BiondVax to present at LD Micro Investor Conference in Los Angeles
BiondVax Pharmaceuticals Ltd, a biotech company specializing in the prevention and treatment of infectious diseases, announced that its Director of Investor Relations, Joshua Phillipson, will present at the LD Micro Main Event XV investor conference in Los Angeles from October 25 to 27, 2022. The presentation will focus on BiondVaxs investment case, including its leadership team, innovative nanosized antibody (NanoAb) platform, pipeline development, in-house GMP biologics manufacturing facility, and key upcoming milestones.
Investment
growth-positive
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19
BiondVax Pharmaceuticals Ltd. has provided updates on its strategic research collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG) for the development of innovative alpaca-derived nanosized antibody (NanoAb) therapies. The collaboration has successfully generated, identified, and isolated NanoAbs for the treatment of diseases such as psoriasis, psoriatic arthritis, asthma, and wet macular degeneration. The company also plans to initiate a preclinical proof-of-concept study of the COVID-19 NanoAb as an inhaled therapy in COVID-19 infected animals.
PartnersExpand
growth-positive
BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies...
BiondVax Pharmaceuticals Ltd. has signed a definitive collaboration agreement with the Max Planck Society and the University Medical Center Göttingen for the development of nanosized antibodies (NanoAbs). The collaboration will focus on conditions such as psoriasis, psoriatic arthritis, asthma, and macular degeneration. BiondVax also recently conducted a webinar showing promising results from a small pilot study in which hamsters were protected from COVID-19 by SARS-CoV-2-specific NanoAbs. The company announced financial results for the fourth quarter and full year 2021, and the European Investment Bank has agreed in principle to extend the maturity date of its loan to BiondVax until December 2027.
PartnersInvestment
Growth-Positive
BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary Shares
BiondVax Pharmaceuticals Ltd. has announced the pricing of an underwritten public offering of 3,813,560 American Depositary Shares (ADSs) at a public offering price of $2.36 per ADS, with gross proceeds to the company of approximately $9.0 million. The company plans to use the net proceeds for the advancement of its recently announced nanosized antibody (NanoAb) development program and for general corporate purposes. The offering is expected to close on December 29, 2021. Aegis Capital Corp. is acting as the sole book-running manager for the offering.
InvestmentPublic Trading
growth-positive
BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany
BiondVax Pharmaceuticals Ltd. has announced a strategic collaboration with the Max Planck Society and the University Medical Center Göttingen to develop and commercialize innovative COVID-19 nanosized antibodies (NanoAbs). The NanoAbs have shown potential in neutralizing the SARS-COV-2 virus at lower drug concentrations than currently available monoclonal antibodies. The collaboration also covers the development of new NanoAbs for other diseases with large market sizes. BiondVax plans to conduct preclinical studies in 2022 and expects initial human clinical trial results in 2023.
PartnersExpand
growth-negative
ביונדווקס חוזרת אחרי קריסת המניה: "מחפשים לפתח חיסונים חדשים"
BeyondVax, an Israeli biotech company, experienced a significant setback when its flu vaccine failed during the height of the COVID-19 pandemic. The companys stock, traded on NASDAQ, lost about 86% of its value in a single day in October, amounting to a loss of approximately $380 million. Despite this, BeyondVax is determined to present a new story to the market, heavily relying on its new CEO, Amir Reichman. The company has managed to raise additional capital and return to a value of $59 million. Reichman brings relevant experience to the role, having previously worked for Novartis and GSK.
Management ChangesInvestment
growth-positive
BiondVax Announces Appointment of Amir Reichman as New CEO
BiondVax Pharmaceuticals Ltd. has announced the appointment of Amir Reichman as its new CEO. Reichman will share duties with the companys founder and current CEO, Ron Babecoff, during a transition period. Reichman currently serves as Head of Global Vaccines Engineering Core Technologies and Asset Management at GlaxoSmithKline (GSK) Vaccines. He will assume the CEO position full time from March 2, 2021, and Babecoff will continue as Senior Advisor to the Company. The company is focused on the development and manufacturing of products for the prevention and treatment of infectious diseases.
Management Changes
growth-negative
Biondvax plunges on failed universal flu vaccine trial
BiondVax Pharmaceuticals Ltd., an Israeli universal flu vaccine developer, saw its share price fall by 86% after the company announced negative results of its phase III clinical trial of M-001, a standalone universal flu vaccine candidate. The trial failed to demonstrate a significant difference between the vaccinated and placebo groups in reducing flu illness and severity. Despite the setback, the company plans to explore options to maximize the value of its assets, including its expertise, IP, and state-of-the-art manufacturing facility.
Investment
growth-positive
BiondVax Announces At-The-Market (ATM) Equity Offering Program
BiondVax Pharmaceuticals Ltd., a developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate, has entered into an agreement with BofA Securities, Citigroup, and Credit Suisse for a $100 million At-The-Market (ATM) equity offering program. The company plans to use the net proceeds from the ATM Program for general corporate purposes, which may include working capital, research and development activities, regulatory matters, capital investment, and pre-commercialization and commercialization activities.
Investment
growth-positive
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
BiondVax Pharmaceuticals has announced the completion of site visits for all participants in the Phase 3 trial of its universal influenza vaccine candidate, M-001. Over 12,400 volunteers aged 50+ were enrolled in the trial across seven European countries. The trial aims to assess M-001s ability to provide clinical protection from circulating influenza strains and to assess its safety. Results are expected by the end of 2020. In addition to the ongoing trial, equipment installation and manufacturing process scale-up in BiondVaxs pilot facility in Jerusalem are in progress.
InvestmentExpand
growth-positive
Flu Season Might Soon Pass, for Good
Jerusalem-based BiondVax Pharmaceuticals is in phase 3 clinical trials for its universal influenza vaccine. The companys vaccine is designed to grant immunity despite the mutating nature of the virus. BiondVax was co-founded in 2003 by CEO and president Ron Babecoff and has received investments from both government bodies and private companies and funds over the years. The company is also in the process of completing the set up of its Jerusalem manufacturing plant and the upscaling of its manufacturing process, necessary steps for regulatory approval.
InvestmentExpand
growth-positive
Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax
Marius Nacht, co-founder of Check Point Software Technologies Ltd., has acquired a controlling stake in BiondVax Pharmaceuticals Ltd., a universal flu vaccine developer. Nacht invested approximately $2.83 million in BiondVax in 2017 and has now invested an additional $16.67 million, making him the companys controlling shareholder with approximately 42% ownership. The company raised $20 million in total via the offering. BiondVax, founded in 2003, is currently conducting phase 3 trials of its vaccine, M-001.
Investment
growth-positive
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
BiondVax Pharmaceuticals Ltd. has announced the successful enrollment of the first participants in the second cohort of the Phase 3 trial of the M-001 universal flu vaccine candidate. The vaccine is designed to improve upon currently marketed strain-specific vaccines. The trial aims to assess the safety and effectiveness of the M-001 vaccine in reducing flu illness and severity in approximately 12,000 adults aged 50 years and older. Results are expected by the end of 2020.
CustomersExpand
growth-positive
aMoon expands investment in BiondVax
BiondVax Pharmaceuticals Ltd., a universal flu vaccine developer, has announced a rights issue led by the aMoon life sciences venture capital fund. aMoon, which already holds a 20% stake in BiondVax, could become the controlling shareholder in the company after the investment. The investment will be subject to approval at the shareholders meeting on May 28. aMoon will invest $4 million in BiondVax with an option to invest a further $10 million. The overall rights issue will range between $14 million and $30 million.
Investment
growth-positive
EIB grants BiondVax €4m for universal flu vaccine
BiondVax Pharmaceuticals Ltd. has announced that the European Investment Bank (EIB) has agreed to extend the 2017 financing agreement by an additional €4 million. The funds will be used to support the ongoing Phase III trial of BiondVaxs M-001 universal flu vaccine candidate in Europe. The original €20 million EIB-BiondVax non-dilutive co-financing agreement was signed in June 2017. The additional €4m, 20% of the original loan, will be given on enrollment of the first participant in the clinical trials second season.
Investment
Growth-Positive
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
BiondVax Pharmaceuticals Ltd., a developer of the M-001 universal influenza vaccine candidate, announced that it will present at the Influenza Vaccines for the World conference in Edinburgh, Scotland. Joshua Phillipson, BiondVaxs Head of Business Development, will provide an overview of the companys achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial. The vaccine candidate, M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza.
Management ChangesExpand
Neutral
http://www.biondvax.com/2018/09/biondvax-to-present-at-influenza-2018-oxford-conference/
The text is a copyright notice for Scinai Immunotherapeutics Ltd, dated 2023. There is no additional information provided about the company, its operations, or any significant events.
growth-positive
Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
BiondVax Pharmaceuticals, an Israeli company developing a universal flu vaccine, has announced it will voluntarily delist from the Tel Aviv Stock Exchange (TASE), while maintaining its listing on NASDAQ. The decision follows a €20m funding agreement from the European Investment Bank and as the company moves towards Phase 3 clinical trials and the construction of a commercial mid-size manufacturing facility. The company will also seek a new Chairman of the Board with relevant global experience to guide it through the anticipated upcoming international Phase 3 trials and global commercialisation.
Public TradingManagement Changes
growth-positive
BiondVax Receives Additional Grant Funding
BiondVax Pharmaceuticals Ltd has announced that the Israel Innovation Authority (IIA) will fund up to 40% of a NIS 2.7 million (approximately US$ 750,000) budget towards the ongoing development of M-001, the Companys Universal Flu Vaccine candidate. The IIA has granted over US$ 6 million in funding to BiondVax since 2006. The non-dilutive grants will become repayable from royalties generated from future sales of BiondVaxs vaccine, once commercially available on the market.
Investment
growth-positive
Marius Nacht fund invests NIS 10.9m in BiondVax
BiondVax Pharmaceuticals has announced an investment of approximately $2.83 million from Angels High Tech Investments Ltd. The investment will be made in exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv Stock Exchange. Following the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of BiondVax. Angels High Tech Investments is a company fully owned by Marius Nacht, co-founder and chairman of Check Point Software Technologies Ltd. BiondVax is currently developing a universal influenza vaccine.
InvestmentPartners
growth-positive
BiondVax Invited to WHO Influenza Vaccine Meeting
BiondVax Pharmaceuticals Ltd has been invited to participate in the Eighth WHO meeting on the development of influenza vaccines that induce broadly protective and long-lasting immune responses. The meeting is part of the Global Vaccine Action Plan (GVAP) which aims for at least one licensed universal influenza vaccine by 2020. BiondVaxs M-001 is recognized as a leading universal flu vaccine candidate, having completed 5 clinical trials, and with two ongoing Phase 2 trials sponsored by the EUs UNISEC and the US NIH/DMID.
Partners
growth-positive
A vaccine that will eliminate flu
BiondVax, an Israeli company, has patented a vaccine with the potential to eradicate all strains of flu. The company is currently in late Phase 2 clinical trials. Israel’s National Authority for Technological Innovation will fund up to 40 percent of a $920,000 project towards the ongoing development of the vaccine.
InvestmentExpand
growth-positive
Flu vaccine co Biondvax raises $9.5m in Nasdaq IPO
BiondVax Pharmaceuticals Ltd., a developer of universal flu vaccines, has raised $10 million on Nasdaq. The funds were raised at a 25% discount on the companys closing price on the Tel Aviv Stock Exchange. The gross proceeds to BiondVax from this offering are expected to be $9.55 million before deducting underwriting discounts and commissions and other estimated offering expenses. The companys CEO, Ron Babecoff, stated that the US IPO represents a vote of confidence by international investors in the company and its technology.
InvestmentPublic Trading
BiondVax Receives $1.3M Grant From Chief Scientist
